Predicting Treatment Outcomes in Patients With Psoriatic Arthritis or Axial Spondyloarthritis: An Artificial Intelligence-Driven Approach (2026)
https://pubmed.ncbi.nlm.nih.gov/41093647/

Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab (2025)
https://pubmed.ncbi.nlm.nih.gov/40487540/

Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial (2024)
https://pubmed.ncbi.nlm.nih.gov/38228361/

Clinical Relevance of Axial Radiographic Damage in Axial Spondyloarthritis: Evaluation of Functional Consequences by an Objective Electronic Device (2023)
https://pubmed.ncbi.nlm.nih.gov/37061230/

Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional study (2022)
https://pubmed.ncbi.nlm.nih.gov/35368376/

Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab (2022)
https://pubmed.ncbi.nlm.nih.gov/35674938/

Successful Evaluation of Spinal Mobility Measurements With the Epionics SPINE Device in Patients With Axial Spondyloarthritis Compared to Controls (2021)
https://pubmed.ncbi.nlm.nih.gov/34393107/

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. (2020)
https://pubmed.ncbi.nlm.nih.gov/31604704/

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study (2020)
https://pubmed.ncbi.nlm.nih.gov/32378070/

Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/30418704/

Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. (2016)
https://pubmed.ncbi.nlm.nih.gov/26865599/

Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety (2016)
https://pubmed.ncbi.nlm.nih.gov/27049733/

Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. (2016)
https://pubmed.ncbi.nlm.nih.gov/26865599/